The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide
olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide · OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 · Tablet, Film Coated · Oral · Slate Run Pharmaceuticals, LLC
NDC 70436-0014-06 · 90 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- analysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- ANDA210718
- TE code
- AB
- Approval date
- May 14, 2025
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide (Tablet, Film Coated)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 10 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 10 mg/1; AMLODIPINE BESYLATE 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 20 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Slate Run Pharmaceuticals, LLC | AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide — NDC 70436-0014-06," retrieved September 3, 2026, https://drugdashboards.com/drug/70436001406.
Free to cite with attribution — see how the data is put together.